Related Experiment Video
Updated: May 20, 2026
Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
Expression and inhibition of ADAMDEC1 in craniopharyngioma cells
Jianguo Xu1, Liang Liu, Xiaomei Zheng
1Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China. Jianguo_1229@sina.com
Background And Purpose:
Craniopharyngioma is a common intracranial tumor characterized by high recurrence rate and poor prognosis in spite of multidisciplinary approaches. The ADAM-like decysin 1 (ADAMDEC1) is a member of a disintegrin and metalloprotease (ADAM) family which correlates with tumor progression and aggressive behavior. This study aimed to detect and inhibit expression of ADAMDEC1 in order to see whether craniopharyngioma cell growth could be suppressed.
Methods:
ADAMDEC1 expression was detected by Western Blot analysis and reverse transcription-polymerase chain reaction (RT-PCR). Craniopharyngioma cells, which were obtained from tumor samples after surgical removal, were cultured with or without tamoxifen. MTT assay was used to examine tumor cell growth.
Results:
ADAMDEC1 mRNA was expressed in craniopharyngioma cell cultures, but it was not shown in normal brain tissue. Tamoxifen not only reduced ADAMDEC1 mRNA and protein expression, but also inhibited craniopharyngioma cell proliferation.
Conclusions:
ADAMDEC1 may serve as a novel marker for craniopharyngiomas, and tamoxifen could inhibit craniopharyngioma cell growth and ADAMDEC1 expression.
Insights
ADAMDEC1 is expressed in craniopharyngioma cells and linked to tumor growth. Tamoxifen treatment reduced ADAMDEC1 expression and suppressed craniopharyngioma cell proliferation, suggesting a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Craniopharyngioma is a common brain tumor with a high recurrence rate.
- ADAM-like decysin 1 (ADAMDEC1), a member of the ADAM family, is implicated in tumor progression and aggressive behavior.
Purpose of the Study:
- To detect ADAMDEC1 expression in craniopharyngioma cells.
- To investigate the effect of tamoxifen on ADAMDEC1 expression and craniopharyngioma cell growth.
Main Methods:
- ADAMDEC1 expression was analyzed using Western Blot and RT-PCR.
- Craniopharyngioma cells were treated with tamoxifen.
- Cell proliferation was assessed using MTT assay.
Main Results:
- ADAMDEC1 mRNA was detected in craniopharyngioma cells but not in normal brain tissue.
- Tamoxifen significantly reduced ADAMDEC1 mRNA and protein levels.
- Tamoxifen inhibited the proliferation of craniopharyngioma cells.
Conclusions:
- ADAMDEC1 may serve as a novel diagnostic marker for craniopharyngiomas.
- Tamoxifen demonstrates potential in inhibiting craniopharyngioma cell growth by downregulating ADAMDEC1.
More Related Videos
11:00Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
Published on: June 23, 2023
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
Related Concept Videos
01:09GPCRs Regulate Adenylyl Cylase Activity
Two...
02:23Abnormal Proliferation
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...